Consultant in Haemato-Oncologist | Barts Health NHS Trust
| Posting date: | 04 February 2026 |
|---|---|
| Salary: | Not specified |
| Additional salary information: | £109,725 - £145,478 per annum |
| Hours: | Full time |
| Closing date: | 06 March 2026 |
| Location: | London, EC1A 7BE |
| Company: | Barts Health NHS Trust |
| Job type: | Permanent |
| Job reference: | 7785541/ |
Summary
Consultant Haemato-Oncologist with an interest in Myeloma & associated Plasma Cell Disorders
St Bartholomew’s Hospital (travel between all sites of Barts Health might be required)
10 PAs
This post is for a Substantive Consultant to join the Department of Haemato-Oncology at the Barts Cancer Centre, based at St Bartholomew’s Hospital in the City of London.
Barts Health NHS Trust is a provider of an extended network for the care of patients with haematological malignancies and is one of the six Level 3 facilities within London.
The Barts Myeloma team was recently assessed as Excellent when awarded Clinical Service Excellence Program status by Myeloma UK and has a large and varied clinical trials portfolio.
The successful candidate will join the existing multi-disciplinary team in the provision of specialist inpatient and outpatient services to patients with MGUS, Smouldering Myeloma, Multiple Myeloma, Amyloidosis, MGRS and other MGCS.
The post holder will be expected to work three outpatient clinics a week; two general Myeloma clinics weekly, and about one-in-three weeks Autografting clinic, supervising the nurse led MGUS and Revlimid Maintenance clinic on other weeks.
They will be expected to deliver weekday specialist Myeloma ward attending for about 14 weeks a year including leading two ward rounds a week and coordination of a multi-disciplinary team of specialist nurses, doctors in training and allied health professionals.
They will be expected to contribute to the clinical research program through leading on and actively recruiting patients to clinical trials. They will be encouraged to participate in national societies and working groups to help lead on scientific progress, education and advocacy in this field.
There is an expectation that the post-holder will contribute substantially to a program of ambitious Myeloma service development supported by their colleagues. Specifically they will be expected to explore how to best manage capacity challenges and patient and staff experience in the outpatient service, explore and contribute to cross-site working, ambulatory care and revamp the local and network-wide Myeloma educational program. It is expected that for the first 3 years the post holder will be responsible for the Junior Resident Doctor recruitment, induction and rota supervision, after which time this will rotate to another consultant colleague.
They will contribute to the weekend ward attending service covering all Haemato-Oncology inpatients out of hours on an approximately 1 in 14 rota.
Barts Health is one of the largest NHS trusts in the country, and one of Britain’s leading healthcare providers.
The Barts Health group of NHS hospitals is entering an exciting new era on our improvement journey to becoming an outstanding organisation with a world-class clinical reputation. Having lifted ourselves out of special measures, we now have the impetus and breathing space to chart a fresh course in which we are continually striving to improve all our services for patients.
Our vision is to be a high-performing group of NHS hospitals, renowned for excellence and innovation, and providing safe and compassionate care to our patients in east London and beyond. That means being a provider of excellent patient safety, known for delivering consistently high standards of harm-free care and always caring for patients in the right place at the right time. It also means being an outstanding place to work, in which our WeCare values and behaviours are visible to all and guide us in how we work together.
We strive to live by our WeCare values and are committed to promoting inclusion, where every staff member has a sense of belonging. We value our differences and fully advocate, cultivate and support an inclusive working environment.
This advert closes on Sunday 1 Mar 2026